Compare Mutual Funds

Insights from Fund Comparison

• Both Nippon India Pharma Fund (G) and SBI Comma Fund (G) are Sectoral / Thematic, Equity schemes. Nippon India Pharma Fund (G) is 21 yrs 10 m old and manages ₹8,306.35 Crs, whereas SBI Comma Fund (G) is 20 yrs 9 m old with ₹999.26 Crs.
• Nippon India Pharma Fund (G) is therefore older and larger, which may indicate more experience and investor confidence.
• Nippon India Pharma Fund (G) has its top 3 sectors in Pharmaceuticals (73.95%), Healthcare (20.31%), and Retail (3.70%), while SBI Comma Fund (G) focuses on Steel (21.21%), Mining & Mineral products (11.03%), and Crude Oil & Natural Gas (10.88%).
• The funds are completely different in sector allocation, which could result in very different performance patterns based on sector trends.
• Nippon India Pharma Fund (G) holds Sun Pharmaceutical Industries Limited (13.08%), Lupin Limited (7.99%), Divi's Laboratories Limited (6.56%), Dr. Reddy's Laboratories Limited (5.81%), and Cipla Limited (5.67%), whereas SBI Comma Fund (G) holds Tata Steel Ltd. (9.09%), Oil & Natural Gas Corporation Ltd. (7.08%), Reliance Industries Ltd. (5.06%), Vedanta Ltd. (4.85%), and TREPS (4.58%).
• The funds have completely different top holdings, which means their performance could diverge significantly depending on which stocks or sectors lead the market.
• In terms of risk profile, Nippon India Pharma Fund (G) has 99.68% equity and 0.00% debt, while SBI Comma Fund (G) has 95.43% equity and 0.29% debt.
• Nippon India Pharma Fund (G) is more aggressive with higher equity allocation, which could lead to higher returns but more volatility.
• Nippon India Pharma Fund (G) outperformed SBI Comma Fund (G) in 3 Months, 3 Years (returns: -5.27%, 21.49% ) but underperformed in 6 Months, 1 Year, 5 Years (returns: -3.18%, 1.72%, 13.94%). This mixed performance indicates strength in certain market cycles while highlighting periods of relative weakness, suggesting selective timing or careful monitoring may be needed.